Elevated levels of CD40L in SS individuals and heightened transcripts of CD40L in CD4+ T cells highlight the potential of targeting CD40 with the inhibitory monoclonal antibody Iscalimab as a viable treatment option for SS (141). Here, CD4 is linked to synovial sarcoma.